Patents by Inventor Heather Arnett

Heather Arnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
    Publication number: 20230192802
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: August 23, 2022
    Publication date: June 22, 2023
    Applicant: Amgen Inc.
    Inventors: Heather ARNETT, Sabine Schadow ESCOBAR, Ryan Michael SWANSON, Joanne Louise VINEY
  • BTNL3 proteins, nucleic acids and antibodies and uses thereof
    Patent number: 11459370
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 4, 2022
    Assignee: Amgen Inc.
    Inventors: Heather Arnett, Sabine Schadow Escobar, Ryan Michael Swanson, Joanne Louise Viney
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20220056144
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 24, 2022
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220031708
    Abstract: Provided is a method of treating idiopathic pulmonary fibrosis (IPF) using an agent that reduces or eliminates the kinase activity of checkpoint kinase 1 (Chk1).
    Type: Application
    Filed: July 15, 2021
    Publication date: February 3, 2022
    Inventors: Asim Siddiqui, Heather Arnett, Linda De Young, Tarangini Deshpande
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20190359724
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 10421813
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 24, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • BTNL9 proteins, nucleic acids, and antibodies and uses thereof
    Patent number: 10357561
    Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 23, 2019
    Inventors: Heather A. Arnett, Sabine S. Escobar, Ryan M. Swanson, Joanne L. Viney
  • BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
    Publication number: 20190169259
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: January 24, 2019
    Publication date: June 6, 2019
    Applicant: Amgen Inc.
    Inventors: Heather ARNETT, Sabine Schadow ESCOBAR, Ryan Michael SWANSON, Joanne Louise VINEY
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20180002429
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: July 11, 2017
    Publication date: January 4, 2018
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9738721
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: August 22, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20170218076
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9663571
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 30, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9593163
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 14, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20170008958
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 12, 2017
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20160137739
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 19, 2016
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • BTNL9 Proteins, Nucleic Acids, and Antibodies and Uses Thereof
    Publication number: 20150344554
    Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: May 5, 2015
    Publication date: December 3, 2015
    Inventors: Heather A. ARNETT, Sabine S. ESCOBAR, Ryan M. SWANSON, Joanne L. VINEY
  • BTNL3 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF
    Publication number: 20150166630
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 18, 2015
    Inventors: Heather Arnett, Sabine Schadow Escobar, Ryan Michael Swanson, Joanne Louise Viney
  • BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF
    Publication number: 20130101590
    Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: April 8, 2011
    Publication date: April 25, 2013
    Inventors: Heather A. Arnett, Sabine S. Escobar, Ryan M. Swanson, Joanne L. Viney